Amantadine for chronic hepatitis C:: a magic bullet or yet another dead duck?

被引：19

作者：

Craxì, A ^{[1
]}

Lo Iacono, O ^{[1
]}

机构：

[1] Univ Palermo, Med Clin, I-90127 Palermo, Italy

来源：

JOURNAL OF HEPATOLOGY | 2001年 / 35卷 / 04期

关键词：

D O I：

10.1016/S0168-8278(01)00184-2

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：527 / 530

页数：4

共 34 条

[1]

Adinolfi LE, 2000, HEPATOLOGY, V32, p352A

[2] Amantadine for chronic hepatitis C:: pilot study in 14 patients [J].

Andant, C ;

Lamoril, J ;

Deybach, JC ;

Jouet, P ;

Soulé, JC .

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2000, 12 (12) :1319-1322

[3] Pilot study of interferon-α high-dose induction therapy in combination with ribavirin plus amantadine for nonresponder patients with chronic hepatitis C [J].

Berg, T ;

Naumann, U ;

Wiedenmann, B ;

Hopf, U .

ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2001, 39 (02) :145-+

[4] Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C [J].

Brillanti, S ;

Levantesi, F ;

Masi, L ;

Foli, M ;

Bolondi, L .

HEPATOLOGY, 2000, 32 (03) :630-634

[5]

Brillanti S, 1999, ITAL J GASTROENTEROL, V31, P130

[6] HCV RNA levels during therapy with amantadine in addition to interferon and ribavirin in chronic hepatitis C patients with previous nonresponse or response/relapse to interferon and ribavirin [J].

Carlsson, T ;

Lindahl, K ;

Schvarcz, R ;

Wejstal, R ;

Uhnoo, I ;

Shev, S ;

Reichard, O .

JOURNAL OF VIRAL HEPATITIS, 2000, 7 (06) :409-413

[7] Interferon plus amantadine versus interferon alone in the treatment of naive patients with chronic hepatitis C: a UK multicentre study [J].

Caronia, S ;

Bassendine, MF ;

Barry, R ;

Mills, P ;

Naoumov, NV ;

Fox, R ;

Lowes, J ;

Hollanders, D ;

Murray-Lyon, L ;

Irving, WL ;

Goldin, RD ;

Foster, GR .

JOURNAL OF HEPATOLOGY, 2001, 35 (04) :512-516

[8]

Chung RT, 1999, HEPATOLOGY, V30, p354A

[9] Antiviral drugs: current state of the art [J].

De Clercq, E .

JOURNAL OF CLINICAL VIROLOGY, 2001, 22 (01) :73-89

[10] Pegylated (40 kDa) interferon alfa-2A (PEGASYS®) in new combination therapies:: A report of a randomized, multicenter efficacy and safety study [J].

Di Bisceglie, AM ;

Bernstein, DE ;

Rustgi, VR ;

Gitlin, N ;

Jeffers, LJ ;

Simon, D ;

Campagna, J ;

Pappas, SC .

JOURNAL OF HEPATOLOGY, 2001, 34 :143-143

← 1 2 3 4 →